secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2025-09-30T23:59:59+00:00
Accession:  0001815776-25-000062
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LENZ Therapeutics launches VIZZ eye drop for presbyopia in U.S.; samples shipped
--------------------------------------------------------------------------------

- VIZZ (aceclidine 1.44%) first FDA-approved aceclidine-based eye drop for presbyopia, now commercially available.
- Professional sample distribution to optometrists and ophthalmologists initiated nationwide.
- Commercial product shipments to consumers via ePharmacy starting October; broad availability by mid-Q4 2025.
- 93% of Phase 3 CLARITY trial participants achieved 20/40 near vision within 30 minutes, lasting up to 10 hours.
- Addresses ~128 million U.S. adults with blurry near vision; CEO calls it a 'Category of One'.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000181577625000062/0001815776-25-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000181577625000062/lenz-20250930.htm
  HTML page:      https://secwatch.observer/filing/0001815776-25-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer